Search Result

Results for "

glucose lowering

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (2) SGLT (4) 11β-HSD (1) Adenylate Cyclase (1) Akt (6) AMPK (9) Amylases (1) Amyloid-β (2) Apoptosis (6) Autophagy (1) Cannabinoid Receptor (1) CDK (2) Cholinesterase (ChE) (1) DAPK (1) Dipeptidyl Peptidase (3) E1/E2/E3 Enzyme (1) Endogenous Metabolite (14) ERK (3) Fluorescent Dye (1) FOXO (2) Free Fatty Acid Receptor (4) G protein-coupled Bile Acid Receptor 1 (1) GCGR (7) GLP Receptor (4) Glucokinase (6) Glucosylceramide Synthase (GCS) (1) Glutathione Peroxidase (1) Glycosidase (2) GPR119 (1) HCV (2) HIV (2) Insulin Receptor (2) Integrin (2) Interleukin Related (3) Isotope-Labeled Compounds (5) JAK (2) JNK (2) Keap1-Nrf2 (2) KLF (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (4) NF-κB (3) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (2) PDHK (1) PDK-1 (1) PI3K (3) PKC (2) Potassium Channel (4) PPAR (12) Reactive Oxygen Species (ROS) (7) Reference Standards (7) Salt-inducible Kinase (SIK) (2) Sirtuin (3) SOD (1) STAT (2) TNF Receptor (3) Toll-like Receptor (TLR) (2) β-catenin (2)
By Research Areas:	Cancer (12) Cardiovascular Disease (5) Endocrinology (8) Infection (4) Inflammation/Immunology (12) Metabolic Disease (76) Neurological Disease (14)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Glucose-6-Phosphate Isomerase (GPI) GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14771A

Imeglimin hydrochloride 5+ Cited Publications EMD 387008 hydrochloride	Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Metabolic Disease
Imeglimin hydrochloride (EMD 387008) is an oral glucose-lowering agent. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function .

HY-14771

Imeglimin 5+ Cited Publications EMD 387008	Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Metabolic Disease
Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function .

HY-W005629

Leelamine	Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Others	Metabolic Disease
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-N3015

Bruceine E	Others	Metabolic Disease
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-169926

AK-4	Mitochondrial Metabolism	Cancer
AK-4 is a glucose-lowering agent, acting function as a mitochondrial uncoupler .

HY-117978

LY2922083	Free Fatty Acid Receptor	Endocrinology
LY2922083 and related compounds LY2881835 and LY2922470 are spiperidine and tetrahydroquinolinic acid derivatives that are potent GPR40 agonists. LY2922083 activates GPR40 in response to elevated blood glucose and has the potential to be a glucose-lowering agent .

HY-162703

Lipid-lowering agent-2	AMPK	Metabolic Disease
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC₅₀ of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .

HY-159696

ISIS 449884	GCGR	Metabolic Disease
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696A

ISIS 449884 sodium	GCGR	Metabolic Disease
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-138842

DDN	Insulin Receptor Akt ERK	Metabolic Disease
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .

HY-101064

Fmoc-leucine N-FMOC-leucine; NPC 15199; NSC 334290	PPAR	Metabolic Disease
Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-101637

Reglitazar JT 501	PPAR	Metabolic Disease
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .

HY-N6935

Sennidin B	HCV Akt GLUT	Infection Metabolic Disease
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-U00036A

Naveglitazar LY519818	PPAR	Metabolic Disease
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-N1503R

Methyl deacetylasperulosidate (Standard) 6α-Hydroxygeniposide (Standard); Deacetylasperulosidic acid methyl ester (Standard)	Reference Standards Others	Metabolic Disease
Methyl deacetylasperulosidate (Standard) is the analytical standard of Methyl deacetylasperulosidate. This product is intended for research and analytical applications. Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-19843A

MK-0941 free base	Glucokinase	Metabolic Disease
MK-0941 free base is an orally active glucokinase activator, with EC₅₀s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .

HY-169411

α-Glucosidase-IN-77	Glycosidase	Metabolic Disease
α-Glucosidase-IN-77 (Compound H7) is a non-competitive inhibitor for α-glucosidase with an IC₅₀ of 1.25 μM. α-Glucosidase-IN-77 lowers blood glucose levels, improves glucose tolerance, regulates intestinal microbiota, and exhibits hepatoprotective effect in mouse type 2 diabetes model .

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-15671A

GKA50 quarterhydrate	Glucokinase	Metabolic Disease
GKA50 quarterhydrate is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats .

HY-U00036

Naveglitazar racemate LY519818 racemate	PPAR	Metabolic Disease
Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-112488

EXEL-0346	Glucosylceramide Synthase (GCS)	Metabolic Disease
EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC₅₀ of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-19904B

(+)-Adomeglivant (+)-LY2409021	Endogenous Metabolite	Metabolic Disease
(+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia .

HY-162586

PDHK-IN-7	PDHK	Cancer
PDHK-IN-7 (compound 32) is an inhibitor of pyruvate dehydrogenase kinase with an IC₅₀ value of 17 nM.PDHK-IN-7 activates PDH in rat livers and has a glucose-lowering effect in Zucker fatty rats .

HY-148684

AMPK activator 10	AMPK	Metabolic Disease
AMPK activator 10 is an orally active, potent AMPK activator with EC₁₅₀ of 44.3 nM by cell-ELISA. AMPK activator 10 increases the phosphorylation levels of ACC. AMPK activator 10 exhibits a glucose lowering effect .

HY-N8214

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside	Others	Cardiovascular Disease
Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-101064S2

Fmoc-leucine-d3 N-FMOC-leucine-d₃; NPC 15199-d₃; NSC 334290-d₃	PPAR	Metabolic Disease
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-101064S3

Fmoc-leucine-d10	PPAR	Metabolic Disease
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-108328

Nerigliatin PF-04937319	Glucokinase	Neurological Disease Metabolic Disease
Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC₅₀ value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.

HY-N6935R

Sennidin B (Standard)	Reference Standards HCV Akt GLUT	Infection Metabolic Disease
Sennidin B (Standard) is the analytical standard of Sennidin B. This product is intended for research and analytical applications. Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-12735

SCH 900822	GCGR	Metabolic Disease Endocrinology
SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .

HY-143291

AChE-IN-9	Cholinesterase (ChE)	Neurological Disease
AChE-IN-9 is a Tacrine (HY-111338) glycoconjugate tethered with acetylated β-Glucose. AChE-IN-9 is also an AChE inhibitor with an IC₅₀ value of 0.4 μM, with lower hepatotoxicity on healthy cells. Tacrine is used in Alzheimer's research .

HY-P3491

Pegloxenatide Polyethylene glycol loxenatide; PEX 168	GCGR PI3K Akt Reactive Oxygen Species (ROS) Autophagy Interleukin Related Sirtuin AMPK Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications .

HY-13956A

(R)-Pioglitazone-d1 (R)-U 72107-d₁	Endogenous Metabolite	Inflammation/Immunology
(R)-Pioglitazone-d1 ((R)-U 72107-d1) is a stabilized and deuterated R-enantiomer of pioglitazone, exhibiting pharmacological properties that are beneficial for NASH treatment, including modulation of mitochondrial function, non-steroidal anti-inflammatory effects, and glucose-lowering capabilities.

HY-107129

MK-3577	GCGR	Metabolic Disease
MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .

HY-173347

BLINK11	CDK	Neurological Disease
BLINK11 is a BBB-penetrant CDK5 inhibitor. BLINK11 lowers CDK5 activity for both complexes CDK5/p35 (IC₅₀ = 17.09 nM) and CDK5/p25 (IC₅₀ = 14.69 nM). BLINK11 offers anti-diabetic and neuroprotective benefits. BLINK11 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice .

HY-173348

BLINK15	CDK	Neurological Disease
BLINK15 is a BBB-penetrant CDK5 inhibitor. BLINK15 lowers CDK5 activity for both complexes CDK5/p35 (IC₅₀ = 29.34 nM) and CDK5/p25 (IC₅₀ = 12.08 nM). BLINK15 offers anti-diabetic and neuroprotective benefits. BLINK15 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice .

HY-12413A

BMS-986118	Free Fatty Acid Receptor	Metabolic Disease
BMS-986118 is a potent, orally active, and selective GPR40 agonist with an EC₅₀ of 0.07 µM. BMS-986118 has dual insulinotropic and GLP-1 secretory effects, resulting in robust plasma glucose lowering effects in acute animal models .

HY-170572

PB01	Dipeptidyl Peptidase Reactive Oxygen Species (ROS)	Metabolic Disease
PB01 is a DPP-4 inhibitor with an IC₅₀ of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .

HY-117459

E-3030 free acid	PPAR	Metabolic Disease
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

HY-B2099

Buformin 1-Butylbiguanide	AMPK	Metabolic Disease Cancer
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-103023

CLP290 1 Publications Verification	Potassium Channel	Neurological Disease
CLP290 is an orally available activator of the neuron-specific K ⁺-Cl ^- cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .

HY-B2099A

Buformin hydrochloride 3 Publications Verification 1-Butylbiguanide hydrochloride	AMPK	Cancer
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

Cat. No.	Product Name	Type

HY-116215

2-NBDG

60+ Cited Publications

Fluorescent Dyes/Probes

2-NBDG is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes.

Cat. No.	Product Name	Target	Research Area

HY-P3491

Pegloxenatide Polyethylene glycol loxenatide; PEX 168	GCGR PI3K Akt Reactive Oxygen Species (ROS) Autophagy Interleukin Related Sirtuin AMPK Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Iridoids Classification of Application Fields Terpenoids Source classification Rubiaceae Metabolic Disease Plants Disease Research Fields Hedyotis diffusa Willd.	Others
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-N3015

Bruceine E	Simaroubaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr.	Others
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

HY-N6935

Sennidin B	Infection other families Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Metabolic Disease Plants Cassia angustifolia Disease Research Fields	HCV Akt GLUT
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-W012241

Dodecanedioic acid	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-N2179

Hypaphorine 1 Publications Verification	Alkaloids Neurological Disease Classification of Application Fields Caragana korshinskii Leguminosae Source classification Eupatorium triplinerve Vahl. Metabolic Disease Abrus precatorius Linn. Plants Disease Research Fields	p38 MAPK JNK
Hypaphorine is an indole found in Caragana korshinskii. Hypaphorine has neurological and glucose-lowering effects. Hypaphorine prevents Lipopolysaccharides (LPS) (HY-D1056)-mediated acute lung injury (ALI) and proinflammatory response via inactivating the p38/JNK signaling pathway by upregulating DUSP1 .

HY-N1503R

Methyl deacetylasperulosidate (Standard) 6α-Hydroxygeniposide (Standard); Deacetylasperulosidic acid methyl ester (Standard)	Iridoids Terpenoids Source classification Rubiaceae Plants Hedyotis diffusa Willd.	Reference Standards Others
Methyl deacetylasperulosidate (Standard) is the analytical standard of Methyl deacetylasperulosidate. This product is intended for research and analytical applications. Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-N8214

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside	Cardiovascular Disease Flavonols Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	Others
Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .

HY-N6935R

Sennidin B (Standard)	other families Leguminosae Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Cassia angustifolia Plants	Reference Standards HCV Akt GLUT
Sennidin B (Standard) is the analytical standard of Sennidin B. This product is intended for research and analytical applications. Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-N2179R

Hypaphorine (Standard)	Alkaloids Caragana korshinskii Leguminosae Source classification Eupatorium triplinerve Vahl. Abrus precatorius Linn. Plants	p38 MAPK JNK
Hypaphorine is an indole found in Caragana korshinskii. Hypaphorine has neurological and glucose-lowering effects. Hypaphorine prevents Lipopolysaccharides (LPS) (HY-D1056)-mediated acute lung injury (ALI) and proinflammatory response via inactivating the p38/JNK signaling pathway by upregulating DUSP1 .

HY-W012241R

Dodecanedioic acid (Standard)	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-N1570

Pterosin B	other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Pteridium aquilinum Inflammation/Immunology Disease Research Fields Pteridiaceae	Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-N1570R

Pterosin B (Standard)	other families Ketones, Aldehydes, Acids Source classification Plants Pteridium aquilinum Pteridiaceae	Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-N0527

Pentagalloylglucose Maximum Cited Publications 12 Publications Verification Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose	Infection other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields	JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) E1/E2/E3 Enzyme
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .

HY-N0527R

Pentagalloylglucose (Standard) Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)	other families Source classification Phenols Polyphenols Plants	Reference Standards JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS)
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .

HY-N2110R

Phellopterin (Standard)	Source classification Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants	Reference Standards Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.

HY-N2110

Phellopterin	Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Inflammation/Immunology Disease Research Fields	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-N3021R

D-chiro-Inositol (Standard)	Natural Products Source classification Endogenous metabolite	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N7075

Inulin 3 Publications Verification	Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Source classification Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Saccharides Sophora tomentosa L.	Endogenous Metabolite
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

Cat. No.	Product Name	Chemical Structure

HY-101064S2

Fmoc-leucine-d3
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-101064S3

Fmoc-leucine-d10
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-W012241S1

Dodecanedioic acid-d4

Dodecanedioic acid-d₄ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W012241S

Dodecanedioic acid-d20

Dodecanedioic acid-d₂₀ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-13956A

(R)-Pioglitazone-d1
(R)-Pioglitazone-d1 ((R)-U 72107-d1) is a stabilized and deuterated R-enantiomer of pioglitazone, exhibiting pharmacological properties that are beneficial for NASH treatment, including modulation of mitochondrial function, non-steroidal anti-inflammatory effects, and glucose-lowering capabilities.

HY-14771S

Imeglimin-d3
Imeglimin-d₃ (EMD 387008-d₃) is deuterium labeled Imeglimin. Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function .

HY-B2099S

Buformin-d9 hydrochloride
Buformin-d₉ (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-W777762

Dodecanedioic Acid-13C12

Dodecanedioic Acid- ¹³C₁2 is the ¹³C-labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

Cat. No.	Product Name		Classification